Prominex develops molecular diagnostic assays and a point-of-care testing platform for infectious diseases. Its Validex System incorporates novel molecular amplification and waveguide detection technologies to enable ultrafast, multiplexed, low-cost molecular assays. The company plans to use the new funding to advance development of its infectious disease assays and to commence an instrument development partnership with Invetech. Prominex completed a $4M Series A-1 financing to support these product and instrument efforts. The company was founded in 2016 by Paul Thomas and is based in San Diego, California. The financing reflects current investment in its assay and instrument development programs.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2018